Abstract

Solithromycin is a novel agent of macrolide antimicrobial classes that demonstrates treatment option in community-acquired pneumonia (CAP). It showed bactericidal effect against major respiratory tract pathogens namely, Streptococcus pneumonia, Staphylococcus aureus and Haemophilus influenza even against strains exhibiting resistance to commonly used antibiotics. Solithromycin demonstrates broadspectrum antibacterial activity together with other features like intracellular accumulation and antiinflammatory effect. It showed moderately severe adverse events during clinical trails and demonstrated favourable tissue penetration and pharmacokinetic properties. Solithromycin showed non-inferiority to moxifloxacin in clinical trial indicating its possible treatment option in CAP and other lower respiratory tract infections in the future. This commentary describes recent advances regarding solithromycin that has been introduced into clinical trials.